WO2007066158A2 - HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF - Google Patents

HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF Download PDF

Info

Publication number
WO2007066158A2
WO2007066158A2 PCT/HU2006/000091 HU2006000091W WO2007066158A2 WO 2007066158 A2 WO2007066158 A2 WO 2007066158A2 HU 2006000091 W HU2006000091 W HU 2006000091W WO 2007066158 A2 WO2007066158 A2 WO 2007066158A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
dienogest
process according
hydroxy
estra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2006/000091
Other languages
French (fr)
Other versions
WO2007066158A3 (en
Inventor
Lajosné DANCSI
Sándor MAHÓ
Antal Aranyi
János HORVÁTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Nyrt
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK06808800.4T priority Critical patent/DK1963354T3/en
Priority to AU2006323005A priority patent/AU2006323005B2/en
Priority to PL06808800T priority patent/PL1963354T3/en
Priority to EA200801508A priority patent/EA014558B1/en
Priority to JP2008543921A priority patent/JP5399711B2/en
Priority to CA2631748A priority patent/CA2631748C/en
Priority to BRPI0619428A priority patent/BRPI0619428B8/en
Priority to CN2006800515980A priority patent/CN101360757B/en
Priority to US12/096,209 priority patent/US8314145B2/en
Priority to EP06808800A priority patent/EP1963354B1/en
Priority to MX2008007243A priority patent/MX2008007243A/en
Priority to AT06808800T priority patent/ATE451383T1/en
Application filed by Richter Gedeon Nyrt, Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Nyrt
Priority to HR20100102T priority patent/HRP20100102T1/en
Priority to DE602006011052T priority patent/DE602006011052D1/en
Publication of WO2007066158A2 publication Critical patent/WO2007066158A2/en
Publication of WO2007066158A3 publication Critical patent/WO2007066158A3/en
Priority to IL191915A priority patent/IL191915A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Definitions

  • the invention relates to a new process for the synthesis of. high purity Ua- cyanomethyl-17 ⁇ -hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I)
  • This compound is used as active ingredient in contraceptive pharmaceutical compositions as progestogene component, in the hormone replacement therapy as well as in compositions against endometriosis.
  • the invention relates also to the high purity 17 ⁇ - cyanomethyl-17 ⁇ -hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient.
  • the pharmaceutical compositions according to this invention contain high purity dienogest according to this invention as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.
  • high purity dienogest means, that the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0,02%),
  • Known procedures for the synthesis of diogenest of formula (I) start from intermediates of the total synthesis of estrone. The main difference between the known procedures is that the two double bonds characteristic for the desired compound are already included in the starting material or not, and in the latter case they are formed in the last step of the synthesis.
  • 2,5(10)-diene ⁇ sed. as starting material can be synthesized by reacting dimethylsulfonium methylide and the 17-oxo derivative obtained by Oppenauer oxidation of the 17-hydroxy group of 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) - latter synthesized by known methods.
  • This compound is hydrolyzed with sulfuric acid to give 17 ⁇ -cyanomethyl-17 ⁇ -hydroxy-estr-5(10)-ene, from which after bromination and subsequent dehydrobromination the dienogest is obtained in 48% yield.
  • the total yield of the process is 24%. ' • .
  • German patent application DD 296,495 describes a one-pot synthesis, according to which first the starting keto-steroid - position 3 of which contains a hydroxy or an oxo group protected with one or more alkoxy group - is reacted with cyanomethyl lithium formed in situ in the reaction of lithium alkyls or lithium dialkylamides and acetonitrile in an organic solvent at low temperature. This way a 17-hydroxy and a 17-cyanomethyl group are formed from the 17 oxo group, the obtained reaction mixture is treated with water and the obtained 17-hydroxy-17-cyanomethyl derivative is isolated or transformed into dienogest by direct acidic hydrolysis.
  • the yield of the final product is 82% starting from 3,3-dimethoxy-estra- 5(10),9(ll)-diene-17-one, while using the 3,3-(l,3-propylenedioxi)-estra-5(10),9(ll)-diene derivative as starting material the yield is 80%.
  • the purity of the product is characterized by the melting point: 208-211.5 0 C.
  • the synthesis consist of 6 steps included the preparation of the 17-oxo derivative used as starting material.
  • the compound of formula (V) can be oxidized by Oppenauer oxidation in good yield (90%) without damaging the A-ring (aromatization). This way we could elaborate a 4-step synthesis, which is shorter than the known procedures.
  • dienogest of formula (I) is synthesized the following way:
  • Step ii) is preferably carried out at a temperature between -10 and -20°C, while step iv) between 25 and 50°C using 1.05 equivalent of pyridinium tribromide.
  • Recrystallization is preferably carried out using acetone, ethyl acetate, acetonitrile, methanol, ethanol, or aqueous mixtures of different ratio of these solvents, as well as mixtures of different ratio of dichloromethane and diisopropyl ether or isopropanol or tert-butyl methyl ether.
  • the so obtained recrystallized product is further purified by preparative HPLC using silica gel as adsorbent and different solvent systems as eluents, such as dichlorornethane/ethyl acetate, dichloromethane/tert-butyl methyl ether, or dichloromethane/acetone.
  • Dichloromethane is evaporated from the eluate and the obtained high purity dienogest is isolated from the other component of the used solvent system, e.g. ethyl acetate, tert-butyl methyl ether, acetone, or diisopropyl ether, methanol, ethanol or aqueous mixtures of different ratio of these solvents.
  • the synthesis can be carried out on industrial scale, increasing the batch size compared to the size described in the Examples do not cause technical problems and do not influence the purity of the final product ' .
  • the yields of the reaction steps of the synthesis are much higher, than yields given in the prior arts.
  • the yield of every step is higher than 80%, therefore the total yield is over 50%.
  • the quality of the synthesized high purity dienogest is better, than the quality requirements of the pharmacopoeia.
  • the amount of impurities is determined by HPLC. According to these measurements in our product the total amount of impurities is less than 0.1% and the amount of 4-bromo-dienogest, which is an impurity detectable in the marketed pharmaceutical compositions in more than 0.1%, is under the detection limit (0.02%).
  • alkali cyanides and dimethylsulfonium derivatives are not used in accordance with environmental regulations and economic considerations, as well as expensive and hazardous butyl lithium is not used either - a hexane solution, of hexyllithium is used instead of them.
  • the precipitated aluminum hydroxide was filtered off and the filtrate was concentrated to a volume of 250 ml under reduced pressure. A mixture of 200 ml of methanol and 100 ml of water was added to this concentrated warm - about 60 0 C - solution, the obtained suspension was cooled to 20-25 °C and stirred for 1 h. The precipitated crystalline product was filtered off and dried below 40 0 C in vacuum to yield 76.4 g (87%) of the title compound.
  • a dynamic axial compression metal column (diameter: 5 cm; iength: 60 cm) was filled with 51O g silica gel (Uetikon C-gel C-490, particle size: 15-35 ⁇ m) suspended in 1400 ml of dichloromethane and the column was conditioned with a 70:30 mixture of dichloromethane/ethyl acetate eluent (2500 ml).
  • a solution of 8.5 g of crude dienogest in .210 ml of dichloromethane was injected to the column and the above mentioned solvent system, was used as eluent with a flow rate of 85 ml/min. UV detector was used for detection.
  • a glass column (diameter: 2.6 cm; length: 46 cm) was filled with 120 g silica gel (Uetikon C-gel C-490, particle size: 15-35 ⁇ m) and the column was conditioned with a 90:10 mixture of dichloromethane/acetone eluent.
  • a solution of 2 g of crude dienogest in 50 ml of dichloromethane was injected to the column and the above mentioned solvent system was used as eluent with a flow rate of 10 ml/min. UV detector was used for detection.
  • a glass column (diameter: 2.6 cm; length: 46 cm) was filled with 120 g silica gel (Uetikon C-gel C-490, particle size: 15-35 ⁇ m) and the column was conditioned with a 90:10 mixture of dichloromethane/acetone eluent.
  • a solution of 2 g of crude dienogest in 50 ml of dichloromethane was injected to the column and the above mentioned solvent system was used as eluent with a flow rate of 10 ml/min. UV detector was used for detection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)

Abstract

The invention relates to a process for the synthesis of high purity 17α- cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I)

Description

fflGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-Q]VE AND PROCESS FOR THE SYNTHESIS THEREOF
The invention relates to a new process for the synthesis of. high purity Ua- cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I)
Figure imgf000003_0001
from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V).
Figure imgf000003_0002
This compound is used as active ingredient in contraceptive pharmaceutical compositions as progestogene component, in the hormone replacement therapy as well as in compositions against endometriosis. The invention relates also to the high purity 17α- cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest according to this invention as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.
In this description high purity dienogest means, that the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0,02%), Known procedures for the synthesis of diogenest of formula (I) start from intermediates of the total synthesis of estrone. The main difference between the known procedures is that the two double bonds characteristic for the desired compound are already included in the starting material or not, and in the latter case they are formed in the last step of the synthesis.
According to the German patent application DD 132,497 3-methoxy-17β-spiro-l',2'- oxirane-estra-2,5(10)-diene is reacted with an alkali metal cyanide to yield a 17α- cyanomethyl-17β-hydroxy-3-enolether derivative. Then the so obtained compound is hydrolyzed, brominated and dehydrobrominated to furnish the dienogest of formula (I) in 32% yield. The purity of the obtained dienogest is characterized by the melting point {204-
214 0C) and optical rotation ([α]^ = -290°, pyridine, c=0.5%). According to the method described in the patent application DD 80,023 3-methoxy-17β-spiro-l',2'-oxirane-estra-
2,5(10)-diene μsed. as starting material can be synthesized by reacting dimethylsulfonium methylide and the 17-oxo derivative obtained by Oppenauer oxidation of the 17-hydroxy group of 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) - latter synthesized by known methods.
The process described in the German patent application DD 160,418 a modification of the above process, in which first the compound of formula (V) is transformed into 3,3- dimethoxy-17-hydroxy-estr-5(10)-ene, the 17 hydroxy group is oxidized with pyridinium chlorocromate - instead of Oppenauer oxidation - then 17β-spiro-l',2'-oxirane is formed with dimethylsulfonium methylide, and the latter is reacted with alkali metal cyanide to obtain 3,3-dimethoxy-17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene. This compound is hydrolyzed with sulfuric acid to give 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene, from which after bromination and subsequent dehydrobromination the dienogest is obtained in 48% yield. The total yield of the process is 24%. ' • .
The German patent application DD 296,495 describes a one-pot synthesis, according to which first the starting keto-steroid - position 3 of which contains a hydroxy or an oxo group protected with one or more alkoxy group - is reacted with cyanomethyl lithium formed in situ in the reaction of lithium alkyls or lithium dialkylamides and acetonitrile in an organic solvent at low temperature. This way a 17-hydroxy and a 17-cyanomethyl group are formed from the 17 oxo group, the obtained reaction mixture is treated with water and the obtained 17-hydroxy-17-cyanomethyl derivative is isolated or transformed into dienogest by direct acidic hydrolysis. The yield of the final product is 82% starting from 3,3-dimethoxy-estra- 5(10),9(ll)-diene-17-one, while using the 3,3-(l,3-propylenedioxi)-estra-5(10),9(ll)-diene derivative as starting material the yield is 80%. The purity of the product is characterized by the melting point: 208-211.5 0C. The synthesis consist of 6 steps included the preparation of the 17-oxo derivative used as starting material.
According to the patent application EP 0776904 3,3-(2,2-dimethylpropylene-l,3- dioxy)-4,5-seco-estr-9-ene-5,17-dione is transformed first to estra-4,9-diene-3,17-dione and the latter to 3,3-ethylenedioxy-estra-5(10),9(ll)-diene-17-one. After reacting with dimethylsulfonium iodide a 17β-spiπ>r,2'-oxirane derivative is obtained which is reacted with potassium cyanide to give 17α-cyanomethyl-17β-hydroxy-estra-5(10),9(ll)-diene-3- ethyleneketal. The ketal group of this compound is hydrolyzed with hydrochloric acid to give the final product dienogest in > 98% purity.
According to the processes starting from the above mentioned 3-methoxy-17-hydroxy- estra-2,5(10)-diene of formula (V) first a 3,3-dialkoxy-ketal-5(10)-ene derivative is formed, then the latter is oxidized to a keto compound, which is reacted with dimethylsulfonium- methylide to give a 17β-spiro-l',2'-oxirane derivative, and this is transformed into 17<X- cyanomethyl-17β-hydroxy derivative. The obtained compound is hydrolyzed with acid, then brominated and dehydrobrominated to yield the dienogest of formula (I) in 6 steps.
According to the other process starting also from compound of formula (V) after the oxidation of the hydroxyl group in position 17 by Oppenauer oxidation the 17β-spiro-l',2'- oxirane derivative is synthesized, which is reacted with alkali metal cyanide, the obtained.3- enolether is hydrolyzed, brominated and dehydrobrominated to yield dienogest in 5 steps.
According to the other method mentioned above 3,3-ethylenedioxy-estra-5(10),9(ll)- diene-17-one is either reacted directly with cyanomethyl lithium or spiro-oxirane is formed first and the oxirane ring is opened with alkali cyanide to give the 17α-cyanomethyl-17β- hydroxy derivative, which is hydrolyzed to yield the final product of formula (I).
The syntheses of the 17β-spiro-l',2'-oxirane derivatives starting from 17-keto compounds and dimethylsulfonium derivatives according to the methods described in patent applications DD 132,497 and EP 0,776,904 are expensive and environmentally not friendly. The use of alkali cyanide for the opening of the oxirane ring requires keeping to strict safety instructions and after the work-up of the reaction mixture causes environmental problems. In the above mentioned patent applications the quality of the product is characterized only by melting point or at most substance content. The requirements of recent , pharmacopoeia specify several other method of examination for the amount of substance and impurities, such as thin layer and liquid chromatography, as well as determine and limit the amount and the number of impurities.
Our aim was to eliminate the above mentioned disadvantages of the known procedures and elaborate a shorter, more economical and environmentally friendly synthesis, which can be carried out on industrial scale preferably using an intermediate of the estrone total synthesis, the 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) as starting material.
Our other aim was to synthesize a high purity product, in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%), therefore it is suitable for producing different formulations of drugs.
Surprisingly it was found, that using the compound of formula (V) as starting material in the synthesis of compound of formula (III) it is not necessary to form the 17β-oxirane derivative, followed by opening the epoxide ring with alkali cyanide, as well as it is not required to synthesize the 3,3-dialkoxy-ketal from the enolether group of compound of formula (V) and oxidize the hydroxyl group in position 17 with pyridinium chlorocromate.
Using the reaction conditions according to our invention the compound of formula (V) can be oxidized by Oppenauer oxidation in good yield (90%) without damaging the A-ring (aromatization). This way we could elaborate a 4-step synthesis, which is shorter than the known procedures.
According to our invention the dienogest of formula (I) is synthesized the following way:
i) 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) is reacted with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating
ii) the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV)
Figure imgf000007_0001
is reacted with cyanomethyl lithium at a temperature between 0 and -3O0C,
iii) the obtained 3-methoxy-17α-cyanomethyl-17β-hydroxy-estra-2,5(10)-diene of formula (III)
Figure imgf000007_0002
is reacted with a strong organic acid in tetrahydrofuran solution,
iv) the obtained 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-oήe of formula (II)
Figure imgf000007_0003
is reacted with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 6O0C, then the obtained crude dienogest of formula (I) is purified by recrystallization and preparative HPLC.
Step ii) is preferably carried out at a temperature between -10 and -20°C, while step iv) between 25 and 50°C using 1.05 equivalent of pyridinium tribromide.
Recrystallization is preferably carried out using acetone, ethyl acetate, acetonitrile, methanol, ethanol, or aqueous mixtures of different ratio of these solvents, as well as mixtures of different ratio of dichloromethane and diisopropyl ether or isopropanol or tert-butyl methyl ether.
In order to obtain high purity the so obtained recrystallized product is further purified by preparative HPLC using silica gel as adsorbent and different solvent systems as eluents, such as dichlorornethane/ethyl acetate, dichloromethane/tert-butyl methyl ether, or dichloromethane/acetone. Dichloromethane is evaporated from the eluate and the obtained high purity dienogest is isolated from the other component of the used solvent system, e.g. ethyl acetate, tert-butyl methyl ether, acetone, or diisopropyl ether, methanol, ethanol or aqueous mixtures of different ratio of these solvents.
Advantages of our process are as follows:
- the synthesis can be carried out on industrial scale, increasing the batch size compared to the size described in the Examples do not cause technical problems and do not influence the purity of the final product ' .
- the starting material of the synthesis, the 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V), is an easily accessible industrial product,
- the synthesis consist of less reaction steps - only 4 - than the processes knowri from the literature - 5-6-8 steps,
- using the reaction conditions according to our invention the yields of the reaction steps of the synthesis are much higher, than yields given in the prior arts. The yield of every step is higher than 80%, therefore the total yield is over 50%.
- the quality of the synthesized high purity dienogest is better, than the quality requirements of the pharmacopoeia. The amount of impurities is determined by HPLC. According to these measurements in our product the total amount of impurities is less than 0.1% and the amount of 4-bromo-dienogest, which is an impurity detectable in the marketed pharmaceutical compositions in more than 0.1%, is under the detection limit (0.02%). - In the cyanomethylation reaction alkali cyanides and dimethylsulfonium derivatives are not used in accordance with environmental regulations and economic considerations, as well as expensive and hazardous butyl lithium is not used either - a hexane solution, of hexyllithium is used instead of them.
The process according to our invention is illustrated by the following not limiting examples.
Example 1
3-Methoxy-estra-2,5(10)-diene-17-one
To a stirred solution of 106.3 g (0.52 mmol) of aluminum isopropoxide in 2000 ml of dry toluene 720 ml of cyclohexanone, 0.35 g of 2,6-ditert-butyl-4-methyl-phenol and 100 g (0.307 mol) 3-methoxy-17-hydroxy-estra-2,5(10)-diene were added, then the reaction mixture was stirred at 108-110 0C for 1 h. The reaction was followed by TLC. After completion of the reaction the mixture was cooled to 20-25 0C, 200 ml of water was added and the so obtained mixture was stirred for 1 h. The precipitated aluminum hydroxide was filtered off and the filtrate was concentrated to a volume of 250 ml under reduced pressure. A mixture of 200 ml of methanol and 100 ml of water was added to this concentrated warm - about 60 0C - solution, the obtained suspension was cooled to 20-25 °C and stirred for 1 h. The precipitated crystalline product was filtered off and dried below 40 0C in vacuum to yield 76.4 g (87%) of the title compound.
Purity: min. 98% (HPLC)
Melting point: 106-110 °C.
Example 2
3-Methoxy-17α-cyanomethyl-17β-hydroxy-estra-2,5(10)-diene
410 ml (1.012 mol) of 2.5 M hexyllithium solution was diluted with 300 ml of dry tetrahydrofuran, the solution was cooled to -20 0C and 58 ml (1.112 mol) of acetonitrile was added. To the so obtained suspension of cyanomethyl lithium a solution of 144.8 g (0.506 mol) of 3-methoxy-estra-2,5(10)-diene-17-one in 1450 ml of tetrahydrofuran was added between -20 and -10 0C and the reaction mixture was stirred between -20 and -10 0C until completion of the reaction - followed by TLC. After completion of the reaction 640 ml of water was added, the organic phase was separated, washed twice with 60 ml of water, and concentrated to a volume of 720 ml under reduced pressure. The concentrated solution was cooled to 20-25 °C, 720 ml of water was added, the precipitated crystalline product was filtered off and dried below 40 0C in vacuum. The obtained crude product was recrystallized from ethanol to yield 143.4 g (86.5%) of the title compound.
Purity: min. 98% (HPLC)
Melting point: 145-150 0C. Example 3
17α-Cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-one
To a stirred solution of 100.8 g (0.8 mol) of oxalic acid dihydrate in 560 ml of water a solution of 131 g (0.4 mol) of 17α-cyanomethyl-17β-hydroxy-3-methoxy-estra-2,5(10)-diene in 1050 ml of tetrahydrofuran was added with cooling. After stirring at 20-25 0C for 1 h the precipitated product was filtered off and dried below 50 0C in vacuum. The obtained crude product was recrystallized from ethyl acetate to yield 107 g (85.6%) of the title compound. Purity: min. 98% (HPLC)
Melting point: 170-175 °C.
Example 4
17α-Cγanomethyl-17β-hγdroxy-estra-4,9-diene-3-one (crude dienogest)
A stirred solution of 142 g (0.45 mol) of 17α-cyanomethyl-17β-hydroxy-estr-5(10)- ene-3-one in 850 ml of pyridine was cooled to 20-25 °C and a solution of 150 g (0.47 mol) of pyridinium tribromide in 640 ml of pyridine was added while the temperature of the reaction mixture was allowed to rise to 50 °C. After stirring for 1 h the reaction mixture was added to a stirred mixture of 320 ml of concentrated sulfuric acid and 5600 ml of water. The precipitated crystals were filtered off and dried below 60 °C in vacuum. The obtained crude product was recrystallized from acetone to yield 116 g (83%) of the title compound.
Amount of active ingredient: min. 97% (HPLC).
4-Bromo-dienogest impurity: max. 1 % (HPLC).
Melting point: 210-213 °C.
[OC]20 D = - 318° (c=l%, dichloromethane). Example 5
Purification of dienogest by preparative HPLC
A dynamic axial compression metal column (diameter: 5 cm; iength: 60 cm) was filled with 51O g silica gel (Uetikon C-gel C-490, particle size: 15-35 μm) suspended in 1400 ml of dichloromethane and the column was conditioned with a 70:30 mixture of dichloromethane/ethyl acetate eluent (2500 ml). A solution of 8.5 g of crude dienogest in .210 ml of dichloromethane was injected to the column and the above mentioned solvent system, was used as eluent with a flow rate of 85 ml/min. UV detector was used for detection. The fractions containing the pure compound (3600 ml) were concentrated, ethyl acetate was distilled off from the residue and the obtained dienogest was recrystallized from ethyl acetate to yield after drying below 60 °C in vacuum 7.53 g (90.6%) of pure dienogest.
Total amount of impurities: maximum 0.1% (HPLC).
Individual impurities: maximum 0.02% (HPLC).
Melting ρoint:211-214 0C.
[α]20 D = -322° (c=l %, dichloromethane).
Example 6
Purification of dienogest by preparative HPLC
A glass column (diameter: 2.6 cm; length: 46 cm) was filled with 120 g silica gel (Uetikon C-gel C-490, particle size: 15-35 μm) and the column was conditioned with a 90:10 mixture of dichloromethane/acetone eluent. A solution of 2 g of crude dienogest in 50 ml of dichloromethane was injected to the column and the above mentioned solvent system was used as eluent with a flow rate of 10 ml/min. UV detector was used for detection. The fractions containing the pure compound (700 ml) were concentrated, acetone was distilled off from the residue and the obtained dienogest was recrystallized from acetone to yield after drying below 60 0C in vacuum 1.77 g (88.5%) of pure dienogest.
Total amount of impurities: maximum 0.1% (HPLC).
Individual impurities: maximum 0.02% (HPLC).
Melting point:211-214 0C.
[α]20 D = -322° (c=l %, dichloromethane).
Example 7
Purification of dienogest by preparative HPLC
A glass column (diameter: 2.6 cm; length: 46 cm) was filled with 120 g silica gel (Uetikon C-gel C-490, particle size: 15-35 μm) and the column was conditioned with a 90:10 mixture of dichloromethane/acetone eluent. A solution of 2 g of crude dienogest in 50 ml of dichloromethane was injected to the column and the above mentioned solvent system was used as eluent with a flow rate of 10 ml/min. UV detector was used for detection. The fractions containing the pure compound (700 ml) were concentrated, acetone was distilled off from the residue and the obtained dienogest was recrystallized from acetone to yield after drying below 60 °C in vacuum 1.77 g (88.5%) of pure dienogest.
Total amount of impurities: maximum 0.1% (HPLC).
Individual impurities: maximum 0.02% (HPLC).
Melting point:211-214 °C.
[Ot]20 D = -322° (c=l %, dichloromethane).

Claims

What we claim is:
1. A new process for the synthesis of high purity 17α-cyanomethyl-17β-hydroxy-estra- 4,9-diene-3-one (further on dienogest) of formula (I)
Figure imgf000014_0001
from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V),
Figure imgf000014_0002
characterized by
i) reacting the 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating
ii) then reacting the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV)
(IV)
Figure imgf000014_0003
with cyanomethyl lithium at a temperature between 0 and -30°C,
iii) then reacting the obtained 3-methoxy-17α-cyanomethyl-17β-hydroxy-estra- 2,5(10)-diene of formula (III)
Figure imgf000015_0001
with a strong organic acid in tetrahydrofuran solution,
iv) reacting the obtained 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-one of formula (II)
Figure imgf000015_0002
with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60°C,
then purifying the obtained crude dienogest of formula (I) by recrystallization and preparative HPLC.
2. The process according to claim 1 characterized by carrying out the oxidation of step i) in toluene in the presence of 20-25 equivalent of cyclohexanone between 100 and 120 0C.
3. The process according to the above claims, characterized by preparing the cyanomethyl lithium reagent of step ii) in situ from hexyllithium and acetonitrile.
4. The process according to the above claims, characterized by carrying out the " cyanomethylation reaction of step ii) between 0 and -30 0C.
5. The process according to the above claims, characterized by carrying out the cyanomethylation reaction of step ii) between -10 and -20 0C. '
6. The process according to the above claims, characterized by using 2 equivalent of cyanomethyl lithium reagent in step ii).
7. The process according to the above claims, characterized by carrying out the acidic treatment of step iii) with a di- or tribasic organic acid in tetrahydrofuran.
8. The process according to the above claims, characterized by carrying out the acidic treatment of step iii) with 2 equivalent of oxalic acid dihydrate.
9. The process according to the above claims, characterized by reacting the compound of formula (II) with 1.05 equivalent of pyridinium tribromide in step iv).
10. The process according to the above claims, characterized by reacting the compound of formula (II) with pyridinium tribromide between 0 and 60 °C in step iv).
11. The process according to the above claims, characterized by reacting the compound of formula (II) with pyridinium tribromide between 25 and 50 °C.
.
12. The process according to the above claims, characterized by purifying the dienogest of formula (I) by HPLC using silica gel as adsorbent.
13. The process according to the above claims, characterized by purifying the dienogest of formula (I) by HPLC using the following solvent mixtures as eluents: 70:30 dichloromethane/ethyl acetate or 80:20 dichioromethane/tert-butyl methyl ether or 90:10 dichloromethane/acetone.
14. The process according to the above claims, characterized by recrystallizing the dienogest of formula (I) obtained by preparative HPLC from ethyl acetate, acetone, tert-butyl methyl ether, diisopropyl ether, acetonitrile, methanol, ethanol or aqueous mixture of different ratio of these solvents.
15. High purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%).
16. Pharmaceutical compositions containing high purity dienogest of. formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo- dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.
PCT/HU2006/000091 2005-12-05 2006-10-11 HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF Ceased WO2007066158A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AU2006323005A AU2006323005B2 (en) 2005-12-05 2006-10-11 High purity 17alpha-cyanomethyl-17beta-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof
PL06808800T PL1963354T3 (en) 2005-12-05 2006-10-11 HIGH PURITY 17alfa-CYANOMETHYL-17beta-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
EA200801508A EA014558B1 (en) 2005-12-05 2006-10-11 HIGH PURITY 17α CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
JP2008543921A JP5399711B2 (en) 2005-12-05 2006-10-11 High purity 17α-cyanomethyl-17β-hydroxy-estradi-4,9-dien-3-one and method for synthesizing the same
CA2631748A CA2631748C (en) 2005-12-05 2006-10-11 High purity 17.alpha.-cyanomethyl-17.beta.-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof
BRPI0619428A BRPI0619428B8 (en) 2005-12-05 2006-10-11 process for the synthesis of 17α-cyanomethyl-17ß-hydroxyestra-4,9-diene-3-one
CN2006800515980A CN101360757B (en) 2005-12-05 2006-10-11 High purity 17alfa-cyanomethyl-17beta-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof
EP06808800A EP1963354B1 (en) 2005-12-05 2006-10-11 HIGH PURITY 17alfa-CYANOMETHYL-17beta-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
US12/096,209 US8314145B2 (en) 2005-12-05 2006-10-11 High purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof
DK06808800.4T DK1963354T3 (en) 2005-12-05 2006-10-11 High-purity 17alpha-cyanomethyl-17beta-hydroxy-estra-4,9-dien-3-one and its synthesis process
AT06808800T ATE451383T1 (en) 2005-12-05 2006-10-11 HIGHLY PURE 17ALFA-CYANOMETHYL-17BETA-HYDROXYÖSTRA-4,9-DIENE 3-ONE AND METHOD FOR THE SYNTHESIS THEREOF
MX2008007243A MX2008007243A (en) 2005-12-05 2006-10-11 High purity 17î±-cyanomethyl-17î²-hydroxy-estra-4,9-diene-3-one and process for the synthesis thereof.
HR20100102T HRP20100102T1 (en) 2005-12-05 2006-10-11 HIGH PURITY 17alfa-CYANOMETHYL-17beta-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
DE602006011052T DE602006011052D1 (en) 2005-12-05 2006-10-11 HIGH-PURITY 17alfa-CYANOMETHYL-17beta-HYDROXYÖSTRA-4,9-DIEN-3-ON AND METHOD FOR THEIR SYNTHESIS
IL191915A IL191915A (en) 2005-12-05 2008-06-03 Process for the synthesis of 17alpha-cyanomethyl-17ß-hydroxy-estra-4,9-diene-3-one

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0501132A HUP0501132A2 (en) 2005-12-05 2005-12-05 17-alpha-cyanomethyl-17betha-hydroxyestra-4,9-diene-3-one of high purity and process for its production
HUP0501132 2005-12-05

Publications (2)

Publication Number Publication Date
WO2007066158A2 true WO2007066158A2 (en) 2007-06-14
WO2007066158A3 WO2007066158A3 (en) 2007-08-09

Family

ID=89986433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2006/000091 Ceased WO2007066158A2 (en) 2005-12-05 2006-10-11 HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF

Country Status (22)

Country Link
US (1) US8314145B2 (en)
EP (1) EP1963354B1 (en)
JP (1) JP5399711B2 (en)
CN (1) CN101360757B (en)
AT (1) ATE451383T1 (en)
AU (1) AU2006323005B2 (en)
BR (1) BRPI0619428B8 (en)
CA (1) CA2631748C (en)
CY (1) CY1110063T1 (en)
DE (1) DE602006011052D1 (en)
DK (1) DK1963354T3 (en)
EA (1) EA014558B1 (en)
ES (1) ES2338047T3 (en)
HR (1) HRP20100102T1 (en)
HU (1) HUP0501132A2 (en)
IL (1) IL191915A (en)
MX (1) MX2008007243A (en)
PL (1) PL1963354T3 (en)
PT (1) PT1963354E (en)
SI (1) SI1963354T1 (en)
UA (1) UA91390C2 (en)
WO (1) WO2007066158A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256128A1 (en) 2009-05-22 2010-12-01 HEYL Chemisch-Pharmazeutische Fabrik GmbH und Co. KG Method for synthesis of dienogest from estrone-3-methylether

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130041166A1 (en) 2010-04-20 2013-02-14 Lupin Limited Process for the preparation of dienogest substantially free of impurities
CN101863947A (en) * 2010-06-29 2010-10-20 沈阳药科大学 A kind of synthetic method of dienogest
CN103304619B (en) * 2013-06-08 2015-12-02 西藏海思科药业集团股份有限公司 A kind of Dienogest compound
HU230788B1 (en) * 2013-12-16 2018-05-02 Richter Gedeon Nyrt Norsteroid intermediates and process for their preparation
WO2017064814A1 (en) * 2015-10-16 2017-04-20 持田製薬株式会社 Dienogest-containing tablet
WO2017064815A1 (en) * 2015-10-16 2017-04-20 持田製薬株式会社 Orally disintegrating tablet containing small-dose drug
CN110357937A (en) * 2018-03-26 2019-10-22 华润紫竹药业有限公司 A compound of dienogest
CN110655551A (en) * 2019-09-23 2020-01-07 华润紫竹药业有限公司 A kind of new single crystal form of dienogest medicine and preparation method thereof
CN114736261A (en) * 2022-05-17 2022-07-12 梯尔希（南京）药物研发有限公司 Synthesis method of 8, 11-diene dexamethasone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391165A (en) * 1966-04-07 1968-07-02 Smith Synthesis of gon-5(10)-enes
DE2718872A1 (en) * 1976-06-14 1977-12-22 Jenapharm Veb METHOD OF MANUFACTURING NEW GONA 4,9 (10) SERVES
DD160418A1 (en) * 1979-05-22 1983-07-27 Kurt Ponsold PROCESS FOR PREPARING 17ALPHA SUBSTITUTED GONA-4,9-DIENES
WO1992000991A1 (en) * 1990-07-09 1992-01-23 Jenapharm Gmbh Process for producing unsaturated 17-alpha-cyanomethyl-17-beta-hydroxysteroids
IL119649A (en) 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of cyclic ketals of 3-keto-5(10), 9(11)-steroid diene derivatives
IT1318491B1 (en) * 2000-04-21 2003-08-25 Ind Chimica Srl PROCESS FOR THE PREPARATION OF A PRECURSOR OF TIBOLONE AND DIESTRADIOL DERIVED STRUCTURALLY RELATED.
ES2337521T3 (en) * 2006-02-17 2010-04-26 Janssen Pharmaceutica N.V. 17-PHOSPHORATED STEROID DERIVATIVES USED AS MODULATORS OF THE PROGESTERONE RECEIVER.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256128A1 (en) 2009-05-22 2010-12-01 HEYL Chemisch-Pharmazeutische Fabrik GmbH und Co. KG Method for synthesis of dienogest from estrone-3-methylether
DE102009041893A1 (en) 2009-05-22 2010-12-02 Heyl Chemisch-Pharmazeutische Fabrik Gmbh & Co. Kg Process for the synthesis of diiron residue starting from estrone-3-methyl ether

Also Published As

Publication number Publication date
HRP20100102T1 (en) 2010-04-30
EA200801508A1 (en) 2008-10-30
BRPI0619428B1 (en) 2021-02-17
PT1963354E (en) 2010-01-06
IL191915A0 (en) 2008-12-29
ATE451383T1 (en) 2009-12-15
MX2008007243A (en) 2008-10-22
ES2338047T3 (en) 2010-05-03
AU2006323005B2 (en) 2013-05-30
DK1963354T3 (en) 2010-04-12
BRPI0619428A2 (en) 2011-10-04
WO2007066158A3 (en) 2007-08-09
EP1963354B1 (en) 2009-12-09
CN101360757A (en) 2009-02-04
US8314145B2 (en) 2012-11-20
CN101360757B (en) 2011-07-20
CA2631748C (en) 2013-12-03
HUP0501132A2 (en) 2007-06-28
US20080287404A1 (en) 2008-11-20
SI1963354T1 (en) 2010-03-31
IL191915A (en) 2016-04-21
JP5399711B2 (en) 2014-01-29
CY1110063T1 (en) 2015-01-14
AU2006323005A1 (en) 2007-06-14
PL1963354T3 (en) 2010-05-31
BRPI0619428B8 (en) 2021-05-25
EP1963354A2 (en) 2008-09-03
JP2009518377A (en) 2009-05-07
UA91390C2 (en) 2010-07-26
DE602006011052D1 (en) 2010-01-21
CA2631748A1 (en) 2007-06-14
EA014558B1 (en) 2010-12-30
HU0501132D0 (en) 2006-01-30

Similar Documents

Publication Publication Date Title
JP3977462B2 (en) 11- (Substituted phenyl) -estradi-4,9-diene derivatives
US5352809A (en) 9-alpha-hydroxy steroids, process for their preparation, process for the preparation of the corresponding 9(11)-dehydro derivatives and pharmaceutical preparations containing such steroids
EP0336521B1 (en) 9-alpha-hydroxy-17-methylene steroids, process for their preparation and their use in the preparation of corticosteroids
HUP0000901A2 (en) 16-Hydroxy-11-(substituted phenyl)estra-4,9-diene derivatives, process for their production and pharmaceutical preparations containing them
EP1963354B1 (en) HIGH PURITY 17alfa-CYANOMETHYL-17beta-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
Nitta et al. The syntheses of the corticoid side chain. I. An improved method for the preparation of 17. ALPHA.-hydroxyprogesterone from androst-4-ene-3, 17-dione.
US8450476B2 (en) Process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-17α-pregn-4-ene-3-one-21-carboxylic acid γ-lactone and key intermediates for this process
JP2677626B2 (en) 17-Substituted Androsta-1,4-dien-3-one Derivatives
CN101061133B (en) Industrial process for the preparation of 17-hydroxy-6β,7β;15β,16β-bis-methylene-3-oxo-17α-pregna-4-ene-21-hydroxyacid gamma-lactone and keys used in the process intermediate
EP0334425A1 (en) Novel delta4 - androstene derivatives
US4843157A (en) 13alpha-alkylgonan-delta 9(11)-5,10-epoxides
HU187551B (en) Process for preparing androstene-17-thiones and -dithioketals
CN110072873A (en) For synthesizing the industrial method of nomegestrol acetate
FI110688B (en) New 11-beta-aryl-4-estrene(s) - exhibiting anti-glucocorticoidal activity and useful for treatment of glaucoma and cushings syndrome
HK1111168B (en) A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 ß,7ß,15 ß,16 ß -BISMETHYLENE-17α-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID γ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2631748

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007243

Country of ref document: MX

Ref document number: 2008543921

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006323005

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006808800

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2600/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200801508

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006323005

Country of ref document: AU

Date of ref document: 20061011

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006323005

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680051598.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12096209

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006808800

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0619428

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080604